GlassScriptPhysician profile
Arshad R Shaikh
NPI 1093913220
$2,799.93
in general payments reported to CMS, 2019-2025
29 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $40.35 · 2021: $135 · 2022: $356 · 2023: $229 · 2024: $947 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.53 |
| Education | $132.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $475.59 | 2021-2025 | Padcev, Xtandi |
| Abbvie INC. | $375.97 | 2023-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $297.82 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $271.45 | 2022-2025 | Opdivo, Opdualag |
| Tempus Ai, INC | $189.12 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $155.17 | 2019-2025 | Polivy |
| Jazz Pharmaceuticals INC. | $145.33 | 2022-2025 | |
| Daiichi Sankyo INC. | $104.38 | 2020-2024 | Injectafer |
| Celgene Corporation | $95.28 | 2023-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $68.46 | 2023-2024 | |
| Glaxosmithkline, LLC. | $62.49 | 2024-2025 | Ojjaara, Blenrep, Jemperli |
| Amgen INC. | $56.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $50.13 | 2019 | |
| Beigene USA, INC. | $49.45 | 2024-2025 | Tevimbra, Brukinsa |
| Morphosys, US INC. | $47.02 | 2022-2023 | Monjuvi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $43.18 | 2024 | |
| Janssen Biotech, INC. | $38.70 | 2023 | Rybrevant, Tecvayli |
| G1 Therapeutics, INC. | $36.46 | 2023 | Cosela |
| Novocure INC. | $34.90 | 2025 | Optune Lua (Novottf-200t) |
| Myriad Genetic Laboratories, INC. | $30.22 | 2022 | |
| Apellis Pharmaceuticals, INC. | $26.52 | 2024 | Empaveli |
| Beone Medicines USA, INC. | $25.93 | 2025 | Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $23.59 | 2021 | |
| Alexion Pharmaceuticals, INC. | $19.31 | 2019 | |
| Fennec Pharmaceuticals, INC. | $18.67 | 2025 | Fyarro |
| Stemline Therapeutics INC. | $17.96 | 2023 | Orserdu |
| Verastem, INC. | $16.33 | 2019 | |
| Kite Pharma, INC. | $12.28 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.